Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2028
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90–95% of all kidney cancer cases. Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women. RCC consists of a heterogeneous group of tumors with distinct genetic and metabolic defects. The major histologic RCC subtype is ccRCC, which represents 80–95% of cases (as shown in Table 2). Other forms of the disease, usually referred as non-clear cell RCC (nccRCC), include papillary RCC (PRCC), chromophobe RCC (ChRCC), translocation carcinoma, medullary carcinoma, and collecting duct carcinoma. At present, metastatic RCC (mRCC) is considered incurable, with only a small minority of patients achieving a complete response (CR) to treatment. However, major advances in the treatment landscape within the past 15 years have significantly improved progression-free survival (PFS) and overall survival (OS).
GlobalData is expecting a total of 7 new entrants to launch over the forecast period in the 8MM from 2018–2028 while specific marketed agents are expected to undergo label expansion. The competition will be particularly fierce in renal cell carcinoma, immune checkpoint inhibitors and combinations thereof competing for market share in the adjuvant setting and in fist-line treatment of metastatic RCC. No drugs are currently in late development for nccRCC leaving the treatment of that population an unmet need within the forecast period.
KEY QUESTIONS ANSWERED
Seven late-stage pipeline agents are going to enter the renal cell carcinoma market from 2018 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
What are the current unmet needs in renal cell carcinoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
What is the market outlook in the 8MM from 2018-2028? Consideration of major patent expiries, launch of new premium priced agents and expected label expansions.
What are the main corporate trends? Who are the current and future players?
Scope
Overview of renal cell carcinoma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline renal cell carcinoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting renal cell carcinoma therapeutics sales in the 8MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global renal cell carcinoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
The main drivers of growth include the anticipated approval and launch of 7 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
The main barriers to growth in the 8MM include the patent expiry of major brands and the short sales opportunity window due to the aggressiveness of the disease.
Among the late-stage pipeline products and marketed agents, TKI inhibitors and immune checkpoint inhibitors are expected to generate the greatest revenues over the forecast period.
The two most important unmet needs in the renal cell carcinoma market include: improved treatments that increase complete response rates and treatment options for refractory patients.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global renal cell carcinoma therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global renal cell carcinoma market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the renal cell carcinoma therapeutics market from 2018-2028.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Aveo Pharma
Bayer
Calithera Biosciences
Xynomic Pharmaceuticals
Eisai
Merck kGaA
AstraZeneca
Betta Pharmaceuticals
Bristol-Myers-Squibb
Exelixis
Merck & Co.
Nektar Therapeutics
Novartis
Pfizer
Roche
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.